<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928148</url>
  </required_header>
  <id_info>
    <org_study_id>SPD465-201</org_study_id>
    <nct_id>NCT00928148</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Multi-Center, Placebo- and Active-Controlled, Crossover Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      This is a phase 2, randomized, multi-center, double-blind, 3-period and 3-treatment crossover&#xD;
      study designed to evaluate the safety and duration of efficacy of SPD465 (50 or 75 mg)&#xD;
      compared with placebo and an immediate release amphetamine salt formulation (25 mg) in adults&#xD;
      with ADHD. The controlled environment used in this study is an analog classroom setting&#xD;
      adapted for a 16-hour adult day.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2004</start_date>
  <completion_date type="Actual">November 20, 2004</completion_date>
  <primary_completion_date type="Actual">November 20, 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the duration of efficacy of SPD465 compared to placebo and immediate release amphetamine formulation in adults with ADHD using the Permanent Product Measure of Performance (PERMP) math test</measure>
    <time_frame>-0.5, 2, 4, 8, 12, 14 and 18 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the duration of efficacy of SPD465 compared with placebo and immediate release amphetamine on ADHD symptoms as determined by the ADHD-rating scale (ADHD-RS)</measure>
    <time_frame>5, 10 and 15 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the duration of efficacy of SPD465 compared with placebo and immediate release amphetamine on ADHD symptoms as determined by the Swanson, Kotkin, Agler, M. Flynn, and Pelham (SKAMP) scale</measure>
    <time_frame>5, 10, and 15 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the impact of SPD465 compared with placebo and immediate release amphetamine on sleep as measured by the modified Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of SPD465 based on occurrence of treatment-emergent adverse events (TEAEs), blood pressure (BP), heart rate, electrocardiogram (ECG), and clinical laboratory findings</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Attention-Deficit/Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>SPD465 (50 or 75 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Immediate Release Amphetamine salt (25 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPD465</intervention_name>
    <description>50 or 75 mg once daily for 7 days</description>
    <arm_group_label>SPD465 (50 or 75 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immediate Release Amphetamine Salt</intervention_name>
    <description>25 mg once daily for 7 days</description>
    <arm_group_label>Immediate Release Amphetamine salt (25 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult men and non-pregnant women between the ages of 18 and 55&#xD;
&#xD;
          -  Confirmed diagnosis of ADHD as defined by the Diagnostic and Statistical Manual of&#xD;
             Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)&#xD;
&#xD;
          -  Baseline ADHD score of at least 24&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Weight less than 100 pounds or greater than 250 pounds&#xD;
&#xD;
          -  Psychiatric diagnosis such as a severe comorbid Axis II or Axis I disorder&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  History of seizures&#xD;
&#xD;
          -  Positive urine drug screen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 23, 2009</study_first_submitted>
  <study_first_submitted_qc>June 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

